'In Remission' Means Nothing to an Underwriter

Your oncologist has used the word remission, and it is the best word you have heard in a long time. But if you are now applying for life insurance, here is something nobody tends to warn you about: a UK insurer does not underwrite that word. There is no box on an underwriter's screen marked "in remission". The word that means so much in the clinic means almost nothing to the person pricing your cover.

That sounds harsh, and it is not meant to. It is actually the key to understanding why one cancer survivor is offered ordinary terms while another with the "same" outcome is postponed. "In remission" is a single label stretched across an enormous range of situations, from a small, early cancer removed years ago to an advanced one treated last spring. An underwriter cannot price a range that wide, so instead of the word, they ask four specific things — and those four decide almost everything.

This page names the four, explains how each one moves the decision, and shows why understanding them puts you in a far stronger position than hoping the word "remission" will carry you. Getting life cover after cancer is common; getting it well starts with speaking the underwriter's language rather than the clinic's.

The short answer: "remission" is not an underwriting category

Remission is a clinical judgement that there is no detectable cancer, or that it is under control. It is enormously important to you and your doctors. But it describes a moment, not a risk profile, and an insurer is being asked to price risk across the whole term of a policy. So the underwriter sets the word aside and reaches for the facts underneath it.

This is not cancer-specific stubbornness. It is the same instinct that makes an underwriter look behind any single label — behind a mental-health diagnosis, behind a hazardous hobby, behind a set of blood results. The word is a headline; underwriting is the article. If you have seen our companion pages on those topics, the move here is identical: replace the label with the specifics.

One distinction is worth drawing before we go further, because people arrive here from two different places. If you are a survivor now applying for new cover, this whole page is for you. If instead you already hold a policy and have had a terminal diagnosis, that is a different mechanism — a possible early payment under the existing cover — which we cover separately in how a life policy can pay early on a terminal diagnosis. This page is about being underwritten afresh after treatment.

Why one word hides wildly different risks

To see why "remission" cannot do the work, look at what it is hiding. A one-centimetre, early-stage cancer, fully removed, with clear margins and no spread, treated four years ago, sits at one end. An advanced cancer that had reached the lymph nodes, treated a few months ago, sits at the other. Both people may be told, truthfully, that they are in remission. Their risk over the next twenty years is not remotely the same.

The national survival figures make the point starkly. Survival after cancer in England varies enormously depending on the type of cancer and, above all, the stage at which it was found — from outcomes where the great majority of people are alive many years later, to cancers where survival is far lower. It is that spread, not the word "remission", that the underwriter is trying to locate you within.

Source: NHS England and the National Disease Registration Service, Cancer Survival in England, cancers diagnosed 2018 to 2022, which reports survival by cancer type and stage.

So when an underwriter looks past "remission", they are not being difficult. They are trying to find out which end of that range you are actually at — and the only way to do that is to ask.

The four things an underwriter asks instead

Almost every cancer underwriting decision turns on four facts. Have these ready and the process is far smoother.

1. How long since active treatment ended. Time is your strongest ally. The further you are from the end of treatment with no recurrence, the lower the assessed risk, because the years immediately after treatment are when recurrence is most likely. This is why the same person can be postponed one year and accepted comfortably a few years later, with nothing else changed but the calendar.

2. The stage. Stage describes how far the cancer had spread when it was found — from small and localised through to advanced. It is one of the most powerful factors in the whole assessment, because it maps closely onto the survival differences in the national data. An early stage is a very different application from a late one.

3. The grade. Grade describes how abnormal the cancer cells looked and, broadly, how aggressively the cancer tends to behave. A low grade behaves more predictably; a high grade attracts closer attention. Stage and grade together tell the underwriter far more than either alone.

4. Node status. Whether the cancer had reached the lymph nodes is a specific, powerful marker of spread, and underwriters ask about it directly. Node-negative and node-positive histories are weighed quite differently, even where the stage looks similar.

Sitting behind those four is a fifth, which is really the frame for the rest: the type of cancer. A breast cancer, a bowel cancer, a melanoma and a lymphoma are underwritten against their own patterns of behaviour and their own recurrence risks, so the weight given to stage, grade and time is not identical across them. This is why a general reassurance from a friend who "got cover two years after treatment" tells you very little — their cancer, stage and grade may bear no relation to yours. The four facts matter precisely because they are specific to you, and the type of cancer is what tells the underwriter which yardstick to measure them against.

Notice what these four have in common: every one of them is on your pathology report and in your oncology letters. You do not have to interpret them — you just need to have them to hand. An FCA-authorised broker can take these four facts to the insurers most comfortable with your particular history, which is exactly the moment to get life insurance quotes rather than applying blind.

How "how long ago" is actually counted

The time question causes more confusion than any other, so it is worth pinning down. Insurers generally count from the date active treatment ended, not from diagnosis. That distinction can be a year or more in your favour, because diagnosis often precedes the end of chemotherapy or radiotherapy by many months.

Ongoing hormone therapy is treated as its own case. Long-term endocrine treatment, taken for years after the acute treatment finishes, is usually not counted as "active treatment" in the same way that chemotherapy is — but insurers differ on exactly how they handle it, which is one more reason the same history produces different offers at different insurers. If you are on long-term hormone therapy, say so clearly and let each insurer apply its own rule rather than assuming the worst.

Where an insurer is not ready to offer terms yet, it will normally tell you the period it wants to see before it will look again. That is a postponement, and it is genuinely useful information — it converts an anxious "no" into a dated "not yet", and it tells you exactly when to reapply.

What the decision looks like, and what to do with it

Cancer applications do not resolve into a plain yes or no. There are three realistic outcomes, and it helps to recognise which one you have received.

• A loading. Cover is offered at a higher premium to reflect the assessed risk. This is a common outcome for a survivor a few years out from treatment, and the loading often reduces if you reapply later with more clear years behind you.
• A postponement. The insurer wants more time to pass before deciding, and states how long. Not a refusal — a diary date.
• A decline. The assessed risk sits outside that insurer's appetite. As with weight-based decisions, which follow the same three-way logic set out in why a weight decision can be a loading, a postponement or a decline, a decline from one insurer is not a verdict from the market, and another insurer's ceiling may sit in a different place.

Two practical points while you are arranging cover. First, if the reason you want the policy is to protect a mortgage, and there is cancer in your family as well as your own history, the interaction of family history with decreasing mortgage cover is worth understanding — we set it out in why family history often costs less on a mortgage policy. Second, make sure the money would actually reach the person you intend. If you are not married, a payout does not automatically go to your partner, a trap we explain in why "next of kin" means nothing if you are not married. Writing the policy in trust or naming the right beneficiary matters as much as getting the cover itself.

Consent, your GP and your oncologist

Insurers do not go rummaging through your records uninvited. To obtain medical information they need your written consent, and with it they can request a targeted report from your GP, and sometimes seek hospital or oncology records where the history is complex. The report is usually specific to the conditions declared, not a blanket copy of everything.

You have rights over this. Under the Access to Medical Reports Act 1988, which applies in England, Wales and Scotland, you can ask to see a report from your own doctor before it goes to the insurer, and correct anything factually wrong in it. That is a safeguard worth using when a cancer history is involved, so that the four facts above are recorded accurately rather than left to be inferred. Answer the application's own questions carefully too — the duty to take reasonable care over your answers is the same one that governs every application, whether the subject is cancer or a history of recreational drug use you would rather not mention. The safest answer is always the accurate one.

Scotland and Northern Ireland

The underwriting is UK-wide: the same four facts — time since treatment, stage, grade and node status — are weighed the same way wherever you live. Cancer does not underwrite differently in Glasgow than in Cardiff.

The one difference is, again, the medical-reports machinery. England, Wales and Scotland operate under the Access to Medical Reports Act 1988; Northern Ireland uses the Access to Personal Files and Medical Reports (Northern Ireland) Order 1991 instead. In both cases you have the right to see a report from your own doctor before it is sent. The substance of the assessment does not change across the UK — only the statute that gives you sight of your own records. Our guide to getting cover with a history, a condition or a job pulls this together with the neighbouring situations.

Frequently asked questions

Does being in remission mean I can get life insurance?

Not by itself. UK underwriters do not use remission as a category. They look at the type of cancer, its stage and grade, whether lymph nodes were involved and how long ago treatment finished. Two people both described as in remission can receive very different decisions, from ordinary terms to a postponement, depending on those specifics.

How long after cancer do UK insurers usually look at?

Most insurers count from the date active treatment ended rather than from diagnosis, and ongoing hormone therapy is usually treated differently from chemotherapy or radiotherapy. Where an application is postponed, the insurer normally states the period it wants to see before it will look again, which tells you exactly when to reapply.

Will the insurer contact my oncologist?

With your written consent an insurer can ask your GP for a targeted report, and it may seek hospital or oncology records where the history is complex. Under the Access to Medical Reports Act 1988 you can ask to see a report from your own doctor before it is sent, and correct anything that is factually wrong.